Skip to main content
. 2023 Apr 20;61(4):2201514. doi: 10.1183/13993003.01514-2022

TABLE 3.

Odds of death at 28 days according to the severity of respiratory impairment at randomisation

Stratification variable Intention-to-treat analysis Per-protocol analysis
MP DM OR (95% CI) p-value# MP DM OR (95% CI) p-value#
None 35/337 (10.4) 41/340 (12.1) 0.84 (0.52–1.36) 0.49 24/279 (7.1) 19/286 (5.6) 1.32 (0.71–2.47) 0.38
PaO2/FIO2 ≥200 mmHg 10/150 (6.7) 10/174 (5.7) 1.17 (0.47–2.89) 0.73 5/123 (4.1) 3/156 (1.9) 2.16 (0.51–9.22) 0.30
PaO2/FIO2 <200 mmHg 23/184 (12.5) 31/163 (19.0) 0.61 (0.34–1.09) 0.10 18/154 (11.7) 16/128 (12.5) 0.93 (0.45–1.90) 0.84
Low-flow oxygen 7/142 (4.9) 13/174 (7.5) 0.64 (0.25–1.65) 0.36 5/122 (4.1) 6/157 (3.8) 1.07 (0.32–3.61) 0.91
HFNC 6/74 (8.1) 6/45 (13.3) 0.57 (0.17–1.90) 0.36 4/66 (3.1) 5/38 (13.2) 0.42 (0.10–1.69) 0.23
NIV 22/120 (18.3) 21/118 (17.8) 1.04 (0.54–2.00) 0.91 15/90 (16.7) 7/89 (7.9) 2.34 (0.91–6.06) 0.08

Data are presented as events n/total events n (%), unless otherwise stated. MP: methylprednisolone; DM: dexamethasone; PaO2/FIO2: ratio of arterial oxygen tension (mmHg) to inspiratory oxygen fraction; HFNC: high-flow nasal cannula; NIV: noninvasive ventilation. #: odds ratio of event among MP group versus DM group, estimated using logistic regression model.